<DOC>
	<DOCNO>NCT01740271</DOCNO>
	<brief_summary>Epirubicin common chemotherapy medication use treatment breast cancer . However , chemotherapy dose calculate base people 's height weight , may accurate way . The purpose study see epirubicin dose base people 's genetic profile well usual method .</brief_summary>
	<brief_title>A Study Genetic Based Chemotherapy Dosing Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Female patient histologically confirm nonmetastatic invasive breast cancer schedule receive least three cycle FEC100 adjuvant neoadjuvant set 2 . Documented pathological evaluation breast cancer hormone receptor ( estrogen receptor [ ER ] , progesterone receptor [ PR ] HER2 status 3 . Eastern Cooperative Oncology ( ECOG ) performance status ≤ 2 4 . A Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % . 1 . Uncontrolled congestive heart failure ( CHF ) angina , history myocardial infarction within 2 month study enrollment , cardiac functional capacity Class III IV define New York Heart Association Classification . 2 . Psychiatric disorder ( ) would interfere consent , study participation , follow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>non-metastatic carcinoma breast chemotherapy</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>neoadjuvant</keyword>
</DOC>